INS and Hyperglycemia: It is believed that GLP-1 analogues effectively slow down gastric emptying (26), small intestinal transit (27), decrease postprandial hyperglycaemia, and regulate endogenous GLP-1 excursions, and incretin-stimulated insulin secretion (24).